



Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

**Semi-Annual
Management Report of
Fund Performance**
May 31, 2011



Caution Regarding Forward-looking Statements

Certain portions of this report, including, but not limited to, “Results of Operations” and “Recent Developments”, may contain forward-looking statements about the Class, including its strategy, risks, expected performance and condition. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” and similar forward-looking expressions or negative versions thereof.

In addition, any statement that may be made concerning future performance, strategies or prospects, and possible future Class action, is also a forward-looking statement. Forward-looking statements are based on current expectations and projections about future events and are inherently subject to, among other things, risks, uncertainties and assumptions about the Class and economic factors. Accordingly, assumptions concerning future economic and other factors may prove to be incorrect at a future date.

Forward-looking statements are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied in any forward-looking statements made by the Class. Any number of important factors could contribute to these digressions, including, but not limited to, general economic, political and market factors in North America and internationally, interest and foreign exchange rates, global equity and capital markets, business competition, technological change, changes in government regulations, unexpected judicial or regulatory proceedings, and catastrophic events.

It should be stressed that the above-mentioned list of important factors is not exhaustive. You are encouraged to consider these and other factors carefully before making any investment decisions and you are urged to avoid placing undue reliance on forward-looking statements. Further, you should be aware of the fact that the Class has no specific intention of updating any forward-looking statements whether as a result of new information, future events or otherwise, prior to the release of the next Management Report of Fund Performance.

Semi-Annual Management Report of Fund Performance as at May 31, 2011 Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

This semi-annual management report of fund performance contains financial highlights but does not contain the complete semi-annual financial statements for the investment fund. You can get a copy of the semi-annual financial statements at your request, and at no cost, by calling 1-800-263-4077, by writing to us at Fidelity Investments, 483 Bay St. Suite 300, Toronto ON M5G 2N7 or by visiting our website at www.fidelity.ca or SEDAR at www.sedar.com.

Security holders may also contact us using one of these methods to request a copy of the investment fund's proxy voting policies and procedures, proxy voting disclosure record or quarterly portfolio disclosure relating to the investment fund.

Management Discussion of Fund Performance

Results of Operations

Fidelity Global Health Care Class ("Class") invests substantially all of its assets in units of its underlying fund, Fidelity Global Health Care Fund ("Underlying Fund").

Fidelity Global Health Care Class, Series B, returned 12.4%, after fees and expenses, for the six-month period ended May 31, 2011. The net returns of the other series of this Class are similar to those of Series B, except for differences attributable to expense structures. By way of comparison, the broad-based benchmark, the MSCI World Index, returned 8.3% (in Canadian dollar terms) for the period under review. The Class outperformed the broad-based benchmark due to an increase in global uncertainty amid sovereign debt problems in select European economies and political tensions in oil-producing Middle East nations, prompting investors to move into defensive sectors such as health care.

The Class' benchmark, the MSCI All Country World Health Care Index, returned 14.0% for the six-month period under review. The Class' underperformance of the benchmark was primarily attributable to security selection in the health care providers and services, pharmaceuticals and life sciences and tools industries. However, holdings in health care equipment and supplies contributed to returns. The Underlying Fund ended the review period with an exposure of 22.1% to health care providers and services, 45.4% to pharmaceuticals and 2.7% to life sciences tools and services, compared with the benchmark exposures of about 13.0%, 62.5% and 3.4%, respectively.

Global equities gained during the six-month period ending May 31, 2011, as investors were encouraged by a revival in consumer sentiment and strong corporate earnings. However, towards the end of the period, growing uncertainty weighed somewhat on sentiment, leading some investors to adopt a more defensive positioning. Against this backdrop, health care stocks fared better than more cyclical sectors as its earnings tend to be less susceptible to a slowdown in economic activity. Investors were also reassured by the industry's ability to cut costs to overcome government austerity measures. In addition, some of the companies with structural growth issues have also shown their intent to improve their positioning by either acquiring promising franchises with significant growth potential, or unlocking value by selling assets.

The Underlying Fund is managed by Hilary Natoff, a member of the Global Equity Team, who has extensive experience in the health care sector. She is a bottom-up stock picker who uses Fidelity's research capabilities to tap the best global investment opportunities in this space.

Over the period, fewer opportunities among pharmaceutical firms led the portfolio manager to reduce the fund's exposure to this sub-sector, where some companies face significant hurdles in the shape of upcoming patent expiries and weak product pipelines. In contrast, exposure to the health care equipment and supplies industry was increased to an overweight, with a particular emphasis on names that are likely to benefit from increasing health care demand from emerging markets. Ms. Natoff also increased exposure to health care providers and services, increasing an overweight position in the industry, owing to attractive valuations and rising health care spending.

From a country perspective, exposure to Switzerland was reduced significantly, while exposure to France was increased. The Underlying Fund ended the period with its largest underweight in the U.S., followed by Switzerland, while France accounted for the largest overweight. The country allocations, however, are driven by the bottom-up stock selection process of the manager rather than top-down macro calls.

Recent Developments

Portfolio manager Hilary Natoff remains upbeat about the health care industry's outlook and continues to find numerous investment opportunities. She expects increased life expectancy and an ageing population to boost demand for medicines and related health care services. Rising disposable incomes and infrastructure build-out in emerging markets, such as China and Brazil, will open up new growth areas for the industry. Meanwhile, lifestyle-related diseases, such as obesity, are becoming more prevalent, which create significant opportunities for those companies with effective treatments to tackle these illnesses. Additionally, she expects mergers and acquisitions to continue, as companies facing patent expiries look to improve their product pipelines. Despite these compelling long-term structural drivers, health care companies' valuations remain attractive, relative to historical levels and other sectors. Ms. Natoff continues to focus on the key secular themes of rising health care demand in emerging markets, affordable treatments, and beneficiaries of aging populations, such as hearing aids, glasses and orthopedic device manufacturers. She looks for companies with strong products and pipelines, low patent risks and limited pricing concerns.

At the end of the review period, the Underlying Fund's largest absolute exposure was to the pharmaceuticals industry, which accounted for 45.4% of the holdings. This also represented the largest underweight position of the Underlying Fund, relative to the benchmark. The manager

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Management Discussion of Fund Performance – continued

believes that rising generic competition, patent expiries on blockbuster drugs and perceived issues with the development pipeline of new drugs continue to pose a threat to the industry. The health care providers and services industry continued to account for the largest overweight position, relative to the benchmark.

Independent Review Committee

Susan E.C. Mey retired from the Independent Review Committee on February 23, 2011, and Helen Meyer was appointed on the same date for a term of three years.

Accounting Standards

Changeover to International Financial Reporting Standards

The Canadian Accounting Standards Board (AcSB) of the Canadian Institute of Chartered Accountants (CICA) had planned to adopt International Financial Reporting Standards (IFRS), as published by the International Accounting Standards Board, effective January 1, 2011. In January 2011, the AcSB deferred the adoption of IFRS for investment companies, which include investment funds. Investment companies may continue to apply existing GAAP standards until fiscal years beginning on or after January 1, 2013.

The manager is reviewing and developing a plan to meet the above timetable for changeover to IFRS. The impact of IFRS on accounting policies and implementation decisions will mainly be in the areas of presentations and disclosures in the financial statements of the Class. Currently, two significant areas that may impact the presentation are IAS 32 Financial Instruments: Presentation, and IAS 27 Consolidated and Separate Financial Statements. The manager is currently assessing the Class' shareholder structure and investments to determine the impact of these standards. The manager has currently not identified any changes that will impact net asset value per share (NAVPS) as a result of the changeover to IFRS. However, this present determination is subject to change resulting from the issuance of new standards or new interpretations of existing standards.

Related Party Transactions

Manager and Portfolio Adviser

The Class is managed by Fidelity Investments Canada ULC (Fidelity). Fidelity is a wholly-owned subsidiary of FMR LLC. FMR LLC is the parent company of a group of subsidiaries collectively known as Fidelity Investments.

Fidelity provides or arranges for the provision of all general management and administrative services required by the Class in its day-to-day operations, including providing or arranging the provision of investment advice, establishment of brokerage arrangements relating to the purchase and sale of the investment portfolio, bookkeeping, record-keeping and other administrative services for the Class.

The Class' portfolio adviser is Fidelity and it provides investment advisory services to the Class.

As a result of providing investment advisory and management services, Fidelity receives a monthly management fee, based on the average net assets of each Series, calculated daily and payable monthly. The Class paid Fidelity management fees of \$25,000 for the period ended May 31, 2011.

Administration Fee

Fidelity charges the Class a fixed administration fee in place of certain variable expenses. Fidelity, in turn, pays all of the operating expenses of the Class, other than certain specified class costs (e.g. the fees and expenses of the Independent Review Committee, taxes, brokerage commissions and interest charges). The Class pays an annual rate, which is calculated on a tiered basis, based on the average net assets of each Series. The Class paid Fidelity administration fees of \$5,000 for the period ended May 31, 2011.

Financial Highlights

The following tables show selected key financial information about the Class and are intended to help you understand the Class' financial performance for the period end of the years shown. This information is derived from the Class' audited annual and/or unaudited semi-annual financial statements. Please see the front page for information about how you can obtain the Class' annual or semi-annual financial statements.

Series A

	Six-months ended		Periods ended November 30,			
	May 31, 2011	2010	2009	2008	2007	2006
The Series' Net Assets per Share						
Net assets, beginning of period ^{A, G}	\$ 8.0314	\$ 8.1126	\$ 7.5545	\$ 8.8312	\$ 9.0345	\$ 8.5801
Increase (decrease) from operations:						
Total revenue	—	—	.0015	.0002	.0002	—
Total expenses	(.1094)	(.2092)	(.2175)	(.2394)	(.2692)	(.2591)
Realized gains (losses)	.1570	.2786	(.0890)	.0295	.2007	.0760
Unrealized gains (losses)	.9393	(.1022)	.9109	(1.1185)	(.0653)	.6549
Total increase (decrease) from operations^A	.9869	(.0328)	.6059	(1.3282)	(.1336)	.4718
Distributions:						
From income (excluding dividends)	—	—	—	—	—	—
From dividends	—	—	—	—	—	—
From capital gains	—	—	—	—	—	—
Return of capital	—	—	—	—	—	—
Total distributions^{A, B}	—	—	—	—	—	—
Net assets, end of period^{A, G}	\$ 9.0176	\$ 8.0314	\$ 8.1126	\$ 7.5545	\$ 8.8312	\$ 9.0345
Ratios and Supplemental Data						
Net asset value (000s) ^C	\$ 922	\$ 862	\$ 1,406	\$ 1,419	\$ 2,234	\$ 2,618
Shares outstanding ^C	102,298	107,305	173,279	187,823	252,934	289,787
Management expense ratio ^D	2.62%	2.58%	2.90%	2.94%	2.96%	2.98%
Management expense ratio before waivers or absorptions ^D	2.62%	2.58%	3.26%	3.27%	3.14%	3.23%
Portfolio turnover rate ^E	8%	10%	29%	19%	18%	10%
Trading expense ratio ^F	.15%	.22%	.12%	.15%	—%	—%

^A Net assets and distributions are based on the actual number of shares outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of shares outstanding over the financial period. This table is not intended to be a reconciliation of beginning to ending net assets per share.

^B Distributions were paid in cash or reinvested in additional shares of the Class, or both.

^C This information is provided as at period end of the year shown.

^D Management expense ratio is based on total expenses for the stated period and is expressed as an annualized percentage of daily average net asset values during the period.

^E The Class' portfolio turnover rate indicates how actively the Class' portfolio adviser manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Class buying and selling all of the securities in its portfolio once in the course of the year. The higher the Class' portfolio turnover rate in a year, the greater the trading costs payable by the Class in the year, and the greater chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high portfolio turnover rate and the performance of the Class. The portfolio turnover rate is calculated based on the lesser of purchases or sales of securities divided by the weighted average market value of the portfolio securities, excluding short-term securities.

^F The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net assets during the period, based on the Class' pro-rata share of estimated trading costs incurred in each Underlying Fund. Trading expense ratios prior to September 2008 have not been calculated.

^G For fiscal periods beginning on or after October 1, 2006, the net assets per share is calculated in accordance with Section 3855 of the CICA Handbook.

Series B

	Six-months ended		Periods ended November 30,			
	May 31, 2011	2010	2009	2008	2007	2006
The Series' Net Assets per Share						
Net assets, beginning of period ^{A, G}	\$ 8.1389	\$ 8.2071	\$ 7.6263	\$ 8.8823	\$ 9.0697	\$ 8.5970
Increase (decrease) from operations:						
Total revenue	—	—	.0018	.0002	.0002	—
Total expenses	(.1030)	(.1946)	(.2039)	(.2235)	(.2522)	(.2422)
Realized gains (losses)	.1578	.2712	(.1088)	.0251	.2055	.0793
Unrealized gains (losses)	.9513	(.1580)	.8598	(1.0335)	(.2450)	.5762
Total increase (decrease) from operations^A	1.0061	(.0814)	.5489	(1.2317)	(.2915)	.4133
Distributions:						
From income (excluding dividends)	—	—	—	—	—	—
From dividends	—	—	—	—	—	—
From capital gains	—	—	—	—	—	—
Return of capital	—	—	—	—	—	—
Total distributions^{A, B}	—	—	—	—	—	—
Net assets, end of period^{A, G}	\$ 9.1469	\$ 8.1389	\$ 8.2071	\$ 7.6263	\$ 8.8823	\$ 9.0697
Ratios and Supplemental Data						
Net asset value (000s) ^C	\$ 1,751	\$ 1,693	\$ 2,290	\$ 1,918	\$ 1,894	\$ 1,841
Shares outstanding ^C	191,318	207,959	279,029	251,586	213,289	203,038
Management expense ratio ^D	2.43%	2.38%	2.70%	2.74%	2.76%	2.78%
Management expense ratio before waivers or absorptions ^D	2.43%	2.38%	3.07%	3.07%	2.93%	3.02%
Portfolio turnover rate ^E	8%	10%	29%	19%	18%	10%
Trading expense ratio ^F	.15%	.22%	.12%	.15%	—%	—%

^A Net assets and distributions are based on the actual number of shares outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of shares outstanding over the financial period. This table is not intended to be a reconciliation of beginning to ending net assets per share.

^B Distributions were paid in cash or reinvested in additional shares of the Class, or both.

^C This information is provided as at period end of the year shown.

^D Management expense ratio is based on total expenses for the stated period and is expressed as an annualized percentage of daily average net asset values during the period.

^E The Class' portfolio turnover rate indicates how actively the Class' portfolio adviser manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Class buying and selling all of the securities in its portfolio once in the course of the year. The higher the Class' portfolio turnover rate in a year, the greater the trading costs payable by the Class in the year, and the greater chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high portfolio turnover rate and the performance of the Class. The portfolio turnover rate is calculated based on the lesser of purchases or sales of securities divided by the weighted average market value of the portfolio securities, excluding short-term securities.

^F The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net assets during the period, based on the Class' pro-rata share of estimated trading costs incurred in each Underlying Fund. Trading expense ratios prior to September 2008 have not been calculated.

^G For fiscal periods beginning on or after October 1, 2006, the net assets per share is calculated in accordance with Section 3855 of the CICA Handbook.

Financial Highlights – continued

Series F

	Six-months ended		Periods ended November 30,			
	May 31,	2010	2009	2008	2007	2006
	2011					
The Series' Net Assets per Share						
Net assets, beginning of period ^{A, G}	\$ 8.9332	\$ 8.9185	\$ 8.2022	\$ 9.4707	\$ 9.5688	\$ 8.9734
Increase (decrease) from operations:						
Total revenue	—	—	.0017	.0003	.0002	—
Total expenses	(.0636)	(.1201)	(.1354)	(.1474)	(.1646)	(.1576)
Realized gains (losses)	.1751	.2653	(.0876)	.0281	.2153	.0868
Unrealized gains (losses)	1.0643	(.0905)	1.2600	(1.2301)	(1.343)	.3988
Total increase (decrease) from operations^A	1.1758	.0547	1.0387	(1.3491)	(.0834)	.3280
Distributions:						
From income (excluding dividends)	—	—	—	—	—	—
From dividends	—	—	—	—	—	—
From capital gains	—	—	—	—	—	—
Return of capital	—	—	—	—	—	—
Total distributions^{A, B}	—	—	—	—	—	—
Net assets, end of period^{A, G}	\$ 10.0932	\$ 8.9332	\$ 8.9185	\$ 8.2022	\$ 9.4707	\$ 9.5688
Ratios and Supplemental Data						
Net asset value (000s) ^C	\$ 138	\$ 130	\$ 115	\$ 72	\$ 88	\$ 95
Shares outstanding ^C	13,686	14,594	12,891	8,732	9,292	9,882
Management expense ratio ^D	1.37%	1.35%	1.64%	1.69%	1.70%	1.71%
Management expense ratio before waivers or absorptions ^D	1.37%	1.35%	4.57%	6.59%	5.06%	5.00%
Portfolio turnover rate ^E	8%	10%	29%	19%	18%	10%
Trading expense ratio ^F	.15%	.22%	.12%	.15%	—%	—%

^A Net assets and distributions are based on the actual number of shares outstanding at the relevant time. The increase (decrease) from operations is based on the weighted average number of shares outstanding over the financial period. This table is not intended to be a reconciliation of beginning to ending net assets per share.

^B Distributions were paid in cash or reinvested in additional shares of the Class, or both.

^C This information is provided as at period end of the year shown.

^D Management expense ratio is based on total expenses for the stated period and is expressed as an annualized percentage of daily average net asset values during the period.

^E The Class' portfolio turnover rate indicates how actively the Class' portfolio adviser manages its portfolio investments. A portfolio turnover rate of 100% is equivalent to the Class buying and selling all of the securities in its portfolio once in the course of the year. The higher the Class' portfolio turnover rate in a year, the greater the trading costs payable by the Class in the year, and the greater chance of an investor receiving taxable capital gains in the year. There is not necessarily a relationship between a high portfolio turnover rate and the performance of the Class. The portfolio turnover rate is calculated based on the lesser of purchases or sales of securities divided by the weighted average market value of the portfolio securities, excluding short-term securities.

^F The trading expense ratio represents total commissions and other portfolio transaction costs expressed as an annualized percentage of daily average net assets during the period, based on the Class' pro-rata share of estimated trading costs incurred in each Underlying Fund. Trading expense ratios prior to September 2008 have not been calculated.

^G For fiscal periods beginning on or after October 1, 2006, the net assets per share is calculated in accordance with Section 3855 of the CICA Handbook.

Management Fees

Fidelity serves as manager of the Class. The Class pays Fidelity a monthly management fee for its services, based on the average net assets of each Series, calculated daily and payable monthly. Fidelity uses these management fees to pay for sales and trailing commissions to registered dealers on the distribution of the Class shares, as well as for general investment management and administration expenses.

	Series A Shares	Series B Shares	Series F Shares
Management Fees	2.00%	1.85%	0.85%
As a percentage of management fees:			
Dealer Compensation*	30.47	54.05	—
Investment management, administration and other	69.53	45.95	100.00

* Dealer compensation represents cash commissions paid by Fidelity to registered dealers during the period and includes upfront deferred sales charge and trailing commissions. This amount may, in certain circumstances, exceed 100% of the fees earned by Fidelity during the period. For new Classes or Series the amounts presented may not be indicative of longer term operating periods.

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp.

Past Performance


The performance information shown assumes that all distributions made by the investment class in the periods shown were reinvested in additional securities of the investment class. The performance information does not take into account sales, redemption, distribution or other optional charges that would have reduced returns or performance. How the investment class has performed in the past does not necessarily indicate how it will perform in the future.

On January 10, 2005, Fidelity stopped offering Series A with the initial sales charge ("ISC") option and created Series B, which is only available with the ISC option, and transferred the existing Series A ISC shares into the new Series. Series B management fees are lower than Series A. Returns for Series B include the actual returns for shares when they were available as Series A ISC shares.

Year-by-Year Returns

The following bar chart shows the investment class' annual performance for each of the years shown, and illustrates how the investment class' performance was changed from year to year. In percentage terms, the bar chart shows how much an investment made on the first day of each financial year would have grown or decreased by the last day of each financial year.


Series A



^A Since the Commencement of Operation, from September 26, 2001 to November 30, 2001.

^B For the period December 1, 2010 to May 31, 2011.


Series B



^A Since the Commencement of Operation, from September 26, 2001 to November 30, 2001.

^B For the period December 1, 2010 to May 31, 2011.

Series F



^A Since the Commencement of Operation, from September 26, 2001 to November 30, 2001.

^B For the period December 1, 2010 to May 31, 2011.

Fidelity Global Health Care Class of the Fidelity Capital Structure Corp. Summary of Investment Portfolio as at May 31, 2011

Asset Mix

	% of Class' Net Assets
Foreign Equities	96.3
Canadian Equities	1.3
Cash and Cash Equivalent	1.2
Net Other Assets (Liabilities)	1.2

Sector Mix

	% of Class' Net Assets
Pharmaceuticals	45.4
Health Care Providers & Services	22.1
Health Care Equipment & Supplies	21.8
Biotechnology	4.2
Life Sciences Tools & Services	2.7
Others (Individually Less Than 1%)	1.4
Cash and Cash Equivalent	1.2
Net Other Assets (Liabilities)	1.2

Geographic Mix

	% of Class' Net Assets
United States of America	50.5
United Kingdom	6.7
Switzerland	6.0
France	6.0
Germany	5.3
Denmark	4.1
Japan	3.3
Ireland	3.0
Israel	2.8
Brazil	2.0
Canada	1.3
Bailiwick of Jersey	1.2
Iceland	1.0
Others (Individually Less Than 1%)	4.4
Cash and Cash Equivalent	1.2
Net Other Assets (Liabilities)	1.2

Top 25 Issuers

	% of Class' Net Assets
1. Johnson & Johnson	6.7
2. GlaxoSmithKline PLC	5.7
3. Sanofi-Aventis	4.6
4. Bayer AG	3.3
5. Novartis AG	3.2
6. Merck & Co., Inc.	3.1
7. Baxter International, Inc.	2.9
8. Teva Pharmaceutical Industries Ltd.	2.8
9. Novo Nordisk A/S	2.8
10. Covidien PLC	2.7
11. Amgen, Inc.	2.6
12. Medco Health Solutions, Inc.	2.5
13. Roche Holding AG	2.3
14. Fresenius Medical Care AG & Co. KGaA .	2.0
15. McKesson Corp.	1.7
16. Pfizer, Inc.	1.7
17. AmerisourceBergen Corp.	1.7
18. WellPoint, Inc.	1.7
19. Zimmer Holdings, Inc.	1.5
20. C. R. Bard, Inc.	1.4
21. Express Scripts, Inc.	1.4
22. Synthes, Inc.	1.4
23. Terumo Corp.	1.4
24. Hospira, Inc.	1.3
25. Shire PLC	1.2
	63.6

Total Class Net Assets \$2,811,000

The information in the above tables is based on the Class' pro-rata share of the investment in the Underlying Fund.

The summary of investment portfolio may change due to ongoing portfolio transactions of the underlying fund and class. The most recent annual report, semi-annual report, quarterly report or simplified prospectus for the class and/or underlying fund is available at no cost, by calling 1-800-263-4077, by writing to us at Fidelity Investments Canada ULC, 483 Bay St. Suite 300, Toronto ON M5G 2N7 or by visiting our web site at www.fidelity.ca or SEDAR at www.sedar.com.



Fidelity Capital Structure Corp.
407 2nd Street S.W., Suite 1100
Calgary, Alberta T2P 2Y3

Manager and Registrar

Fidelity Investments Canada ULC
483 Bay Street, Suite 300
Toronto, Ontario M5G 2N7

Custodian

CIBC Mellon Trust Company
Toronto, Ontario

Auditor

PricewaterhouseCoopers LLP
Toronto, Ontario

Visit us online at

www.fidelity.ca

or call Fidelity Client Services
at 1 800 263-4077

Fidelity's mutual funds are sold by registered Investment Professionals. Each Fund has a simplified prospectus, which contains important information on the Fund, including its investment objective, purchase options, and applicable charges. Please obtain a copy of the prospectus, read it carefully, and consult your Investment Professional before investing. As with any investment, there are risks to investing in mutual funds. There is no assurance that any Fund will achieve its investment objective, and its net asset value, yield, and investment return will fluctuate from time to time with market conditions. Investors may experience a gain or loss when they sell their units in any Fidelity Fund. Fidelity Global Funds may be more volatile than other Fidelity Funds as they concentrate investments in one sector and in fewer issuers; no single Fund is intended to be a complete diversified investment program. Past performance is no assurance or indicator of future returns. There is no assurance that either Fidelity Canadian Money Market Fund or Fidelity U.S. Money Market Fund will be able to maintain its net asset value at a constant amount. The breakdown of Fund investments is presented to illustrate the way in which a Fund may invest, and may not be representative of a Fund's current or future investments. A Fund's investments may change at any time.